Japanese drug maker Takeda has come to the rescue of the beleaguered Advinus Therapeutics, a Tata group company, according to two persons familiar with the development. Takeda has advanced in the region of $5mn (Rs 28 crore) to Advinus' drug discovery unit in Pune and will get the 'right of first look' at any resulting … Continue reading White knight : Takeda advance gives Advinus reprieve
To put India on the path to universal healthcare (UHC), the Indian government announced that it would triple its spending in the health sector in the 12th Five Year Plan from an average 0.9 per cent of GDP to 2.5 per cent of GDP by 2017. This includes a $5.4 billion plan spanning five years … Continue reading Guest column : Why India needs the private sector to achieve universal healthcare
Given the intense public debate over access to and pricing of patented medicines, academics, policymakers, lawyers, and others have begun to think creatively about what it is that actually incentivises innovation and encourages drug development. While doing so, it is important to identify the points in the R&D process where the failures occur. There are … Continue reading Guest column : Are “prizes” to reward drug R&D a viable alternative to patents?
The issue of controlling foreign direct investment (FDI) in the Indian pharmaceutical sector continues to make headlines with various arms of the government putting forth their own formulas to tame the grasping foreign hand. The Indian Express reports that the ministry of commerce under Anand Sharma would like all FDI proposals - including where foreign … Continue reading FDI in pharma : another punch
Quintiles, the world's largest clinical research organisation, recently organised a media round table on the biosimilars (generic biologics) landscape with senior executives in Mumbai. Here are the key points, including figures, that emerged out of the discussion: -An estimated 277 companies are developing biosimilars worldwide. A company developing a biosimilar may not be fully aware … Continue reading 5 takeaways from Quintiles’ media round-table on biosimilars